Today, we are outlining key highlights from the American Heart Association (AHA) scientific statement, Secondary Prevention After Coronary Artery Bypass Graft Surgery. Coronary artery disease can continue to progress after coronary artery bypass grafting, emphasizing the importance of long-term management and secondary prevention strategies. This 2026 update incorporates new evidence and advancements in secondary prevention and includes practical considerations related to medical therapy, cardiovascular risk reduction, lifestyle interventions, and long-term care after coronary artery bypass graft surgery (CABG).

The following is a rundown of key highlights from the statement. Refer to the full-text version for the complete and most thorough explanation of this scientific statement.  

Practical Considerations for Antithrombotic Therapy After CABG

  • Low-dose aspirin initiated within 6 hours after CABG and continued indefinitely improves graft patency and reduces future cardiovascular events; higher doses offer no incremental benefit and increase gastrointestinal bleeding risk.
  • In patients with acute coronary syndrome (ACS) undergoing CABG, dual antiplatelet therapy (DAPT) for 1 year may be associated with a lower risk of death and cardiac events.
  • In patients with chronic coronary disease, routine DAPT is not indicated. DAPT with aspirin and clopidogrel or ticagrelor can be considered for 1 year to prevent graft failure in patients who are not at high bleeding risk.

Practical Considerations for Lipid Management After CABG

  • Treat to an LDL-C threshold of 55 mg/dL (1.4 mmol/L) as an ideal target and to no higher than 70 mg/dL (<1.8 mmol/L) as an established target. One may consider an alternative target of non–high-density lipoprotein of <85 mg/dL (2.2 mmol/L) or an apolipoprotein B target of ≤0.65 g/L.
  • First-line therapy: High-intensity or maximally tolerated statin therapy aimed at achieving LDL-C target levels.
  • Second-line therapy: If the LDL-C target is not achieved with statins alone, ezetimibe.
  • Third-line therapy: If the combination of statin and ezetimibe still fails to achieve the target, PCSK9 inhibitor, or consider icosapent ethyl if the triglyceride level is between 135 mg/dL (1.5 mmol/L) and 500 mg/dL (5.6 mmol/L).

Practical Considerations for β-Blocker Therapy After CABG

  • Preoperative: No evidence supports β-blocker administration within 24 hours before elective CABG in β-blocker–naive patients.
  • Perioperative: β-blockers are used to prevent atrial fibrillation (AF) in high-risk patients. If already on β-blockers, perioperative continuation is associated with a reduction in AF, as well as with lower 30-day mortality and ventricular arrhythmias in those with left ventricular ejection fraction (LVEF) ≤40%.
  • Long term: Cardioselective β-blockers after CABG are associated with lower rates of major adverse cardiovascular events (MACEs) but no reduction in mortality.

Practical Considerations for Antihypertensive Therapy After CABG

  • Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARBs) are indicated for patients who have a clinical indication other than CABG (previous myocardial infarction (MI), diabetes, heart failure, reduced LVEF, and hypertension).
  • The use of calcium channel blockers for the first postoperative year, with dihydropyridines (eg, amlodipine or nifedipine) preferred over nondihydropyridines (eg, diltiazem or verapamil), may help limit radial artery graft spasm.

Practical Considerations for Previous MI and Left Ventricular Dysfunction Management After CABG

  • In those with previous MI and persistent LVEF <40%, use of an angiotensin receptor-neprilysin inhibitor (ARNi) is considered first line. ACE inhibitors are used if an ARNi is not feasible, and an ARB is used if the patient is ACE inhibitor intolerant, in combination with β-blockers. If persistent with New York Heart Association (NYHA) class II to IV heart failure, LVEF <35%, and estimated glomerular filtration rate ≥30 mL·min−1·1.73 m−2, an MRA is recommended. European Society of Cardiology guidelines further recommend adding an mineralocorticoid receptor antagonist (MRA) as a predischarge medication in those hospitalized with acute heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are beneficial in patients with symptomatic LVEF ≤40%.
  • If feasible, all 4 agents (ie, ARNi or ACE inhibitors, β-blockers, MRA, and SGLT2 inhibitors) may be simultaneously initiated. Team-based strategies such as early follow-up, telemedicine, cardiac rehabilitation (CR), and coordinated handoffs to primary health care professionals support safe and timely implementation.
  • Device therapy: An implantable cardioverter defibrillator is indicated for primary prevention of sudden cardiac death ≥40 days after MI or ≥90 days after revascularization in patients with LVEF <35% and with NYHA class II to III heart failure on GDMT, LVEF ≤30% on GDMT and LVEF ≤40% and inducible sustained ventricular tachycardia or ventricular fibrillation. After CABG, implantation earlier than 90 days postoperatively may be considered.

Practical Considerations for Diabetes Management After CABG

  • For long-term secondary prevention:
    • SGLT2 inhibitors are prioritized in patients with diabetes and a history of CABG regardless of baseline HbA1c. These therapies are to be used primarily for their effect on reducing MACEs and to afford renal protection.
    • SGLT2 inhibitors are prioritized in patients after CABG with heart failure regardless of diabetes status or ejection fraction. These therapies are used primarily for their effect on reducing cardiovascular death and hospitalization for heart failure and cardiorenal events.
    • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are prioritized in post-CABG patients with diabetes or a body mass index (BMI) >27 kg/m2 without diabetes to reduce MACEs regardless of HbA1c.
    • GLP-1 RAs, specifically semaglutide, are prioritized in people with diabetes and concomitant peripheral artery disease to improve functional outcomes and to prevent disease progression.
  • For perioperative considerations:
    • SGLT2 inhibitors should be avoided in people with type 1 diabetes.
    • When clinically appropriate, SGLT2 inhibitors should be withheld 3 days before CABG and restarted once oral intake, including carbohydrate intake, has been initiated postoperatively to reduce the risk of diabetic ketoacidosis.
    • When clinically appropriate, once-weekly GLP-1 RAs should be stopped 1 week before surgery and oral GLP-1 RAs should be stopped 3 days before surgery and resumed when the patient is eating well and bowel motility is restored.

Practical Considerations for Smoking Cessation After CABG

  • Smoking induces graft failure and MACEs. Abstaining from smoking after CABG can lower 5-year mortality risk by 35% and MACEs by 18%.
  • The cardiac surgeon should document smoking status, actively counsel on the importance of smoking cessation, and initiate smoking cessation support preoperatively. Smokers who quit even 4 weeks before CABG have perioperative outcomes comparable to those of never smokers.
  • As with other chronic diseases, longitudinal smoking cessation care benefits from ongoing management by general practitioners or tobacco treatment specialists.

Practical Considerations for CR and Exercise After CABG

  • All patients with chronic coronary artery disease (CAD) and appropriate indications (after recent MI, percutaneous coronary intervention, or CABG) should be referred to CR programs within 4 weeks of discharge to improve outcomes.
  • CR for patients who are undergoing CABG is most robust when it begins preoperatively, continues during hospitalization, and extends into outpatient care.
  • Telerehabilitation offers a flexible and accessible alternative for delivering CR, particularly for older adults or those unable to attend center-based programs.

Practical Considerations for Other Cardiovascular Risk Reduction After CABG

  • In addition to diet and exercise, behavioral weight loss programs emphasize the importance of health behavior change incorporating self-efficacy, goal setting, stimulus control, and stress management and may be incorporated when obesity is present.
  • Effective strategies may target a net negative energy balance through exercise prescriptions that maximize caloric expenditure and dietary counseling to reduce energy intake.
  • Evidence supports the role of pharmacotherapy in achieving meaningful weight loss and reducing MACEs in both patients with and those without diabetes.
  • Influenza and pneumococcal vaccines should be considered in individuals with atherosclerotic cardiovascular disease.
  • Vaccinations for all adults should be discussed and tailored to individual risk profiles.

Practical Considerations for Mental Health Management After CABG

  • Depression and anxiety are common before and after CABG and correlate with an increased incidence of delirium and other complications. It is essential to assess psychosocial risk factors and mood disturbance through clinical interviews or with standardized tools before and after surgery.
  • Targeted interventions to address depression and anxiety, including pharmacotherapy and psychotherapy, may be implemented per established standards. When a selective serotonin reuptake inhibitor is initiated in patients with CAD on antiplatelet therapy, gastroprotective agents are considered.
  • Cardiac prehabilitation and CR programs enhance physical health and alleviate symptoms of depression, anxiety, and hostility.
  • Systematic screening for preexisting conditions can identify frailty and inform personalized rehabilitation strategies, improving outcomes and adherence to secondary prevention after CABG.

Sign up for alerts and stay informed on the latest published guidelines and articles.